REGULATORY
Research-Driven Makers Need Enough Capital Strength to Withstand Discontinuation of R&D Projects: Comprehensive Strategy
Research-driven drug makers will need to bolster their capital strength to weather R&D project terminations and secure topnotch talents to continue rolling out innovative drugs, the Ministry of Health, Labor and Welfare (MHLW) says, proposing that M&As might be an…
To read the full story
Related Article
REGULATORY
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





